abstract |
The invention relates to a process for the manufacture of enantiomerically enriched or pure compounds of formula (I) wherein R<1>, R<2>, R<3>, R<6>, R<7> and Q are defined as in claim 1 as well as their crystalline forms for the treatment of proliferative diseases such as cancer. |